Sign in

    Leah Rush Cann

    Biotechnology Research Analyst at Brookline Capital Markets, LLC

    Leah Rush Cann is a Biotechnology Research Analyst at Brookline Capital Markets, specializing in equity research on life sciences, biotechnology, and medical technology companies. She covers firms such as Exelixis, Kymera Therapeutics, and C4 Therapeutics, consistently issuing rated Buy recommendations and projecting robust revenue growth, including a 15% annual rate for Exelixis and a $40 price target within 12-18 months. Cann began her Wall Street career in 1992 with Oppenheimer & Co., later serving as Managing Director and Senior Biotechnology Analyst at Oppenheimer and Wachovia Securities before joining Brookline in 2020. She holds an MBA from Stetson University, has been twice named an All-Star Analyst by The Wall Street Journal, serves on numerous industry boards, and maintains an active presence in oncology research and consulting, with strong credentials in advanced securities analysis.

    Leah Rush Cann's questions to Syros Pharmaceuticals (SYRS) leadership

    Leah Rush Cann's questions to Syros Pharmaceuticals (SYRS) leadership • Q3 2024

    Question

    Leah Rush Cann asked if more detailed data from the recent AML trial would be presented at a future medical meeting and inquired about the company's plans for its other asset, SY-5609.

    Answer

    Dr. David Roth, Chief Medical Officer, clarified that the complete AML data was already presented at the SOHO meeting. Conley Chee, Chief Executive Officer, addressed SY-5609, stating it is a high-potential asset better suited for a larger pharmaceutical company, and Syros continues to seek business development opportunities for it.

    Ask Fintool Equity Research AI

    Leah Rush Cann's questions to Syros Pharmaceuticals (SYRS) leadership • Q2 2024

    Question

    Leah Rush Cann of Brookline Capital Markets, LLC requested a detailed characterization of the differences between high-risk and low-risk MDS patients, including how they present clinically and what constitutes appropriate study endpoints and treatment paradigms for each group.

    Answer

    Chief Medical Officer Dr. David Roth provided a comprehensive explanation, noting that low-risk MDS is defined by a longer prognosis and symptoms primarily related to anemia, with treatment focused on improving red blood cell counts. In contrast, high-risk MDS is closer to AML, with issues across multiple blood cell lines and a higher blast count. For high-risk patients, the goal is to reduce blasts and achieve a complete response (CR), an endpoint correlated with overall survival and supported by regulators for potential approval.

    Ask Fintool Equity Research AI

    Leah Rush Cann's questions to X4 Pharmaceuticals (XFOR) leadership

    Leah Rush Cann's questions to X4 Pharmaceuticals (XFOR) leadership • Q2 2024

    Question

    Leah Rush Cann asked for a detailed breakdown of the company's fully diluted share count at the end of the second quarter, including prefunded warrants.

    Answer

    Chief Financial Officer Adam Mostafa provided a comprehensive count, stating there are approximately 157 million basic shares, 33 million prefunded warrants, and 75 million cash-only warrants. This brings the total to roughly 275 million fully diluted shares, excluding some significantly out-of-the-money historical warrants.

    Ask Fintool Equity Research AI